HKHikaru Kamo

Hikaru Kamo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hikaru Kamo has a total of 123 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dose and Outcomes of Rehabilitation During Parkinson Hospitalization

    by Hikaru Kamo, Koichi Nagaki, Rachael M. Burke, Tejas R. Mehta, Matthew Aaron Remz, Anne Brooks, Adrianne Smiley, Michael S. Okun, Christopher W. Hess

    Background and ObjectivesRehabilitation during hospitalization for Parkinson disease (PD) is recommended in international guidelines; however, the real-world intensity of inpatient therapy and its ...

  • How Do Oral Medications, Botulinum Toxin Use, and Treatment Burden Change after Deep Brain Stimulation for Dystonia?

    by Hikaru Kamo, Emma Leone, Rohini Kumar, Chase Antilla, Isabelle Gerzenshtein, Arunmozhimaran Elavarasi, Aparna Wagle Shukla

    Background: Deep brain stimulation (DBS) is an established therapy for dystonia; however, the long‐term trajectory of adjunctive treatment burden, including oral medications and botulinum toxin (BoNT) injections, and the likelihood of achieving medication‐free status remain poorly understood, despite important implications for adverse effects, injection burden, and quality of life. Objective: Determine long‐term changes in adjunctive medication burden and the durability of medication‐free status among dystonia patients undergoing DBS. Methods: We retrospectively examined the proportion of dystonia patients requiring oral medications and BoNT therapy after DBS, tracking postoperative changes at 6 months, 1, 3, 5, and 10 years. Factors influencing overall medication burden were evaluated, and the proportion of patients achieving treatment‐free status was determined. Results: Among 100 patients in this cohort (56% generalized dystonia), baseline use of oral medications and BoNT was 85% and 43%, respectively. The proportion requiring oral medications and BoNT declined to ~60% and ~ 20–25% as DBS benefits emerged, with reductions maintained throughout follow‐up. Among those continuing BoNT, dosing remained largely unchanged. The overall medication burden score, calculated by combining oral medications and BoNT, was significantly reduced at all follow‐up intervals, with body distribution influencing the magnitude of reduction. Around one‐third of patients did not require any medications at 10‐year follow‐up. Conclusion: DBS leads to sustained reductions in adjunctive oral medications and BoNT use. At 10‐year follow‐up, around 20% of dystonia patients continued to require BoNT injections, but 30% were completely medication‐free. These data highlight evolving long‐term benefits and inform patient expectations.

  • Reply: The Potential Perils of Pre‐Referral Triage of Deep Brain Stimulation Candidates

    by Patricia J. Graese, Hikaru Kamo, Kelly D. Foote, Justin D. Hilliard, Dawn Bowers, Franchesca Arias, Dimitry S. Davydow, Gregory M. Pontone, Dana L. Ferrara, Dawn M. Schiehser, et al.

  • Open Access

    Rehabilitation strategies for atypical parkinsonian syndromes: A scoping review of progressive supranuclear palsy, multiple system atrophy, corticobasal syndrome, and dementia with Lewy bodies

    by Hikaru Kamo, Satoru Amano, Isabelle K Gerzenshtein, Dinesh K Vuddandam, Koichi Nagaki, Mai Shimizu, My-Vy Tran, Arunmozhimaran Elavarasi, Nikolaus R McFarland, Aparna Wagle Shukla

    Background: Rehabilitation plays a crucial role in maintaining function and independence in neurodegenerative disorders. However, evidence on its effectiveness in atypical parkinsonian syndromes including progressive supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal syndrome (CBS), and dementia with Lewy bodies (DLB) remains fragmented. Objective: This scoping review aimed to comprehensively map the literature on rehabilitation interventions for PSP, MSA, CBS, and DLB, summarize intervention types and outcomes, and identify research gaps. Methods: Following PRISMA-ScR guidelines, we searched PubMed, Embase, Web of Science, and Cochrane Library from inception to May 2025. Eligible studies included peer-reviewed English-language reports on non-invasive rehabilitation such as physical, occupational, and speech therapy. Two independent reviewers screened titles, abstracts, and full texts, with disagreements resolved by consensus or a third reviewer. Results: Sixty studies met inclusion criteria: PSP ( n = 32), MSA ( n = 20), CBS ( n = 5), and DLB ( n = 6). Across disorders, rehabilitation was consistently safe and feasible. Gait and balance training, voice and swallowing therapy, and multimodal programs demonstrated short-term benefits in mobility, speech, and quality of life (Class III–IV based on American Academy of Neurology classification). Conclusions: While rehabilitation may offer functional benefits across atypical parkinsonian syndromes, high-quality evidence remains limited. This analysis highlights significant gaps in care and underscores the need for early, multidisciplinary, and disease-specific interventions to support mobility and safety. Standardized outcome measures and long-term trials are essential to establish sustained efficacy.

  • Open Access

    Tardive Dystonia Described as Tardive Tremor

    by Sarah Gaber, Hikaru Kamo, Christopher W. Hess


  • Long-Term Outcomes of Subthalamic Nucleus and Globus Pallidus Interna Deep Brain Stimulation for Young-Onset Parkinson Disease

    by Grace E. Hey, Hikaru Kamo, Gilberto Perez Rodriguez Garcia, Tejas R. Mehta, Robert Stephen Eisinger, Michael S. Okun, Justin D. Hilliard, Kelly D. Foote, Adolfo Ramirez-Zamora

    Patients with young-onset Parkinson disease (YOPD) commonly experience early motor complications necessitating deep brain stimulation (DBS), and the subthalamic nucleus (STN) and globus pallidus interna (GPi) are the primary DBS targets used for reducing medication use and addressing dyskinesias. This study leveraged both the University of Florida Fixel Institute high volume of DBS operations and the INFORM database to evaluate motor outcomes in a large cohort of patients with YOPD treated with STN or GPi DBS, and addressed the limited available evidence and paucity of data on the long-term effects of these targets applied to YOPD. A single-center retrospective chart review was conducted on a nonrandomized cohort of adult patients with a diagnosis of YOPD treated with STN or GPi DBS between January 1999 and October 2023. Multidisciplinary evaluation was used to choose the anatomical target for each patient. Disease onset, lead location, medications, and mortality were collected and compared between cohorts. Preoperative, 6-month, and 1-, 3-, and 5-year Unified Parkinson's Disease Rating Scale (UPDRS) scores were used to compare motor outcomes. There were 405 patients, and 61.3% received GPi DBS and 37.7% STN DBS. Mean disease duration at surgery was 12.3 (4.2) years for GPi and 11.5 (6.3) years for STN. GPi DBS improved ON UPDRS part 3 scores at 1 year (26.5 [11.84] vs 20.94 [9.09], p = 0.0024), and these scores worsened slightly by 5-year follow-up (20.94 [9.09] vs 24.72 [10.28], p = 0.0491). Unilateral STN DBS showed greater 6-month motor improvement vs unilateral GPi (p < 0.001) and remained stable from 6 months to 3 years (p = 0.3). GPi DBS improved ON UPDRS part 4 scores from baseline to 5 years (8.34 [3.15] vs 4.21 [2.25], p < 0.0001), whereas STN DBS showed no significant change (6.16 [4.21] vs 5.0 [2.98], p = 0.328). Although statistically significant, the changes did not meet the threshold for clinical relevance. This large cohort study assessed long-term outcomes of STN vs GPi DBS when used in the setting of YOPD. Both targets improved motor symptoms at 1 and 5 years. STN offered modest motor benefits and greater medication reduction, while GPi DBS better addressed dyskinesia and motor fluctuations. These findings inform preoperative decision-making, although selection bias based on baseline symptoms remains a limitation of the data set.


  • Midbrain length by the one-line method predicts motor outcome after deep brain stimulation in Parkinson’s disease

    by Hikaru Kamo, Wataru Sako, Genko Oyama, Akimitsu Suda, Masanobu Ito, Hirokazu Iwamuro, Atsushi Umemura, Taku Hatano, Koji Kamagata, Shigeki Aoki, et al.

    Background Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an effective treatment for Parkinson’s disease (PD). The outcome of DBS varies from patient to patient. Objectives We investigated the preoperative changes in the midbrain to predict DBS outcomes. Methods Patients with PD who underwent bilateral STN-DBS at Juntendo University Hospital between June 2019 and October 2020 were included. We compared the Movement Disorders Society Unified Parkinson’s Disease Rating Scale Part III score in the off state 3 months before and 1 year after surgery, and the difference in the score was defined as the motor outcome after DBS. Preoperative magnetic resonance images of the midbrain were evaluated using FreeSurfer and the One-Line Method. Results A total of 34 patients were enrolled. Multiple regression analysis with least squares indicated that the volume of the midbrain measured using FreeSurfer had no significance as an independent variable (p = 0.16), whereas the midbrain length evaluated using the One-Line Method had significance (p < 0.05) when the outcome of motor symptoms was set as the dependent variable. Conclusions We showed that midbrain size evaluated using the One-Line Method was a good predictor of the motor outcome after STN-DBS, but volume measured using FreeSurfer was not. The One-Line Method was considered to detect changes in size specifically in the midbrain tegmentum, which is associated with PD motor symptoms. Thus, we present a simple and useful method for predicting poor outcomes after STN-DBS treatment in patients with PD with disease progression.

  • Urinary Tract Infections in Hospitalized Patients with Parkinson's Disease: Risk Factors and Outcomes

    by Hikaru Kamo, Rachael M. Burke, Tejas R. Mehta, Matthew Remz, Ruina He, Anne Brooks, Adrianne Smiley, Michael S. Okun, Christopher W. Hess

    Background: Urinary tract infections (UTIs) are common complications among hospitalized patients with Parkinson's disease (PD) and are associated with delirium and prolonged hospitalization. Objectives: To determine the prevalence of UTI, identify modifiable risk factors, and evaluate associated outcomes among hospitalized patients with PD. Methods: We conducted a retrospective cohort study using the PINC‐AI Healthcare Database including PD‐related hospitalizations from 2019 to 2023. UTIs diagnosed on admission or during hospitalization were identified, and multivariable analyses were performed. Results: Among more than 321,000 PD hospitalizations, 18.9% were associated with UTI. Emergent admission, inter‐facility transfer, dementia, and indwelling urinary catheter use were independently associated with UTI, whereas male sex was protective. UTI was associated with prolonged length of stay and delirium. Conclusions: UTIs are frequent among hospitalized patients with PD and are associated with several modifiable risk factors. These findings may inform PD‐specific inpatient strategies for UTI prevention and risk stratification.


  • Top Cited Papers

    Five-year risk of cardiovascular events and falling in Parkinson's disease with orthostatic hypotension: A nationwide cohort study

    by Hikaru Kamo, Matthew Remz, Tejas R. Mehta, Rachael M. Burke, Anne Brooks, Adrianne Smiley, Michael S. Okun, Christopher W. Hess


  • Contrasting Effects of Deep Brain Stimulation and Intravenous Levodopa on Local Field Potentials

    by Hikaru Kamo, Jackson N. Cagle, Kara A. Johnson, Joshua K. Wong, Genko Oyama, Mai Shimizu, Hirokazu Iwamuro, Atsushi Umemura, Taku Hatano, Masanobu Ito, et al.

    Background/Objective: Within‐patient comparison of intravenous levodopa and subthalamic nucleus deep brain stimulation effects on neural oscillations and motor function in Parkinson's disease (PD). Methods: Twelve patients with advanced PD and bilaterally implanted subthalamic electrodes underwent five treatment conditions: medication off/stimulation off, placebo infusion, medication on/stimulation off, medication off/stimulation on, and medication on/stimulation on. For each condition, bilateral local field potentials were recorded, and motor function was evaluated using the Movement Disorder Society Unified Parkinson's Disease Rating Scale Part III. Results: Both levodopa and stimulation improved motor scores ( p < 0.01) and reduced low β activity (13–20 Hz). High β activity (21–30 Hz) decreased only during stimulation ( p < 0.01). Finely tuned γ ( FTG ) oscillations (60–90 Hz) appeared most often during combined therapy (68.2%), with peak frequencies entrained to half the stimulation frequency in 93.3% of electrodes, except under 180 Hz stimulation. During intravenous levodopa infusion, FTG emerged with a median latency of 14.3 minutes, frequently before peak plasma levels, and declined in frequency over time. Changes in FTG power correlated with motor improvement ( p < 0.05), whereas placebo had no effect. Conclusions: Levodopa and stimulation exert distinct but complementary effects on oscillatory activity. FTG , rather than β power alone, reflected therapeutic state and was associated with motor improvement without dyskinesia. These findings highlight FTG as a potential biomarker for adaptive stimulation systems in PD . © 2026 International Parkinson and Movement Disorder Society.